Sandostatin Archives

Tag: Sandostatin

This medicine is given to control symptoms such as diarrhea or flushing in patients with certain types of Gastroenteropancreatic NETs (GEPNETs). Classified as a somatostatin analogue.

It is also used to treat acromegaly, when the body produces too much growth hormone, and the hands, feet, face or head grow too large.

Known as Octreotide, Sandostatin is the brand name with suffix LAR (long acting release) indicating the monthly (normally) version.

Octreotide, Octreotide Acetate, Sandostatin, Sandostatin LAR

29 Jun 2025

By Ronny Allan

6 Comments

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With GEP-NET (SORENTO)

Clinical Trials and Research, TreatmentClinical trial, Gastro-entero-pancreatic neuroendocrine tumour (GEP-NET), Lanreotide, Octreotide, Sandostatin, Somatostatin analogues, Somatostatin receptors (SSTR)

Latest on NET. Camurus announces completed enrolment in the Phase 3 SORENTO study of CAM2029 in patients with neuroendocrine tumours December 14, 2023 at 02:01 am EST Lund, Sweden - 14 December 2023 - Camurus (NASDAQ STO: CAMX) today announces completed enrolment in the randomized, active-controlled Phase 3 SORENTO study evaluating the efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with neuroendocrine tumours located in the gastrointestinal tract or pancreas (GEP-NET). "The enrolment of patients in SORENTO has exceeded expectations. Going forward, we will continue to collect data for the primary endpoint assessment of superiority in progression-free survival with CAM2029 compared to…

21 Dec 2023

By Ronny Allan

5 Comments

Clinical Trial of Paltusotine, an oral somatostatin analogue for the Treatment of Carcinoid Syndrome

Clinical Trials and ResearchAcromegaly, Adrenocorticotropic Hormone (ACTH), Biased agonist, Carcinoid syndrome, Clinical trial, CRN00808, Cushing's disease, Hyperinsulinism, Lanreotide, Neuroendocrine tumour (NET), Octreotide, Sandostatin, Somatostatin analogues, Somatostatin receptors (SSTR)

What is Paltusotine Paltusotine is the first oral, once-daily, selectively targeted somatostatin receptor type 2 (SST2) agonist being developed for the treatment of acromegaly and carcinoid syndrome. The method of operation appears to be similar in that it wants to bind to somatostatin receptor 2 (SST2). In the meantime, see short video and note that the drug for Acromegaly is more advanced in pipeline terms (now in Phase 3). In terms of the effect on NETs, these tumours typically over express SST2, somatostatin type 2 receptors. Both SST2 and 3 are involved in apoptosis of neuroendocrine tumour cells.” Paltusotine’s high level…

22 Apr 2021

By Ronny Allan

10 Comments

Generic Somatostatin Analogues for Neuroendocrine Cancer

TreatmentBynfezia Pen, Generic drugs, Lanreotide, Octreo-ratiopharm®, Octreotide, Olatuton®, Sandostatin, Somatostatin analogues, Somatostatin receptors (SSTR), Somatuline Autogel (US: depot)

Generic Somatostatin Analogues. I've covered a lot about somatostatin analogues, particularly the two predominant approved drugs Lanreotide and Octreotide. Octreotide has many particularly in daily shots and more recently in long acting, but Lanreotide being a newer drug has taken a while for generics to appear. I had to study what generic means and it's important to differentiated the brand from the actual drug name as the latter does not normally change. The reason for publication of this blog is because I was concerned to hear patients asking questions about generic lanreotide and octreotide in my private Facebook group where they…

25 Feb 2021

By Ronny Allan

0 Comments

My treatment is a pain in the butt!

TreatmentLanreotide, Octreotide, Sandostatin, Somatostatin analogues, Somatuline Autogel (US: depot)

Share on facebook Facebook Share on twitter Twitter Share on pinterest Pinterest Share on whatsapp WhatsApp Share on email Email The post header is a bit ‘tongue in cheek’ (…. did you see what I did there?) I’m very happy to have this treatment every 4 weeks – I can think of far worse scenarios. When I was first diagnosed, the dreaded word ‘Chemo‘ was discussed. Chemo isn’t particularly effective in treating the lower grades of Neuroendocrine Cancer but it is used extensively at high grade and often in Grade 2 showing more effectiveness in pancreatic NETs. Looking back though,…

20 Dec 2018

By Ronny Allan

7 Comments

Q-Sphera™ – Next Generation Somatostatin Analogue delivery system?

Clinical Trials and Research, Living with Neuroendocrine Cancer, TreatmentClinical trial, MTD201, Q-Octreotide, Q-Sphera, Sandostatin

Update May 2026. There has been no further news about this initiative so it should be assumed that the development has ceased. Internet searches indicate that n late 2022, Midatech announced an acquisition to expand its portfolio and subsequently changed its name to Biodexa Pharmaceuticals PLC. There is no indication on their new website of any treatment in the pipeline for NET. UPDATE: In March 2020, the decision was taken to terminate further in-house development of the MTD201 programme with immediate effect although the asset remains available for licensing. All activities connected with MTD201 have been wound down expeditiously and…

13 Jul 2017

By Ronny Allan

34 Comments

At home with Lanreotide (….and Octreotide)

TreatmentLanreotide, Neuroendocrine, Neuroendocrine cancer, Neuroendocrine tumour (NET), Sandostatin, Somatostatin analogues, Somatuline Autogel (US: depot)

Update 11th Jan 2024. Ipsen decided to change the name for Somatuline Autogel to Lanreotide Ipsen. Clearly to distinguish its product from the generics now rolling out. Not seen similar yet for Somatuline Depot (US). I think after 163 injections (as of May 2023), I think it's safe to say I'm now 'at home' with Lanreotide (Somatuline Autogel - Somatuline Depot elsewhere). I want to talk about Lanreotide here because that is where my experience is. However, below I have included a bit about how patients can get their long-acting Octreotide (Sandostatin LAR) at home too.I was fortunate enough to have…